Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along ...

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...